TOP > News Release > R&D
2010
- 2010.02.03
- DAIICHI SANKYO INITIATES LARGEST SINGLE, DOUBLE-BLIND,RANDOMIZED, PHASE 3 TRIAL FOR TREATMENT AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM
- 2010.02.01
- Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958, a Long-Acting Neuraminidase Inhibitor for the Treatment of Influenza
2009
- 2009.12.11
- Results of a Clinical Phase 3 Trial of an Oral Factor Xa Inhibitor, Edoxaban, in Prevention of Post-Operative Venous Thromboembolism
- 2009.08.10
- Positive top line results from Phase III study (MARVEL) of anti-influenza virus agent 'CS-8958'
- 2009.07.16
- ANALYSIS OF EDOXABAN PHASE II DATA PROVIDES INSIGHT INTO REDUCED BLEEDING EVENTS SEEN IN ONCE-DAILY DOSING
- 2009.02.24
- European Commission Approves EFIENT®(prasugrel)
for Patients with Acute Coronary Syndrome Undergoing PCI
- 2009.02.04
- Prasugrel Receives Unanimous Approval Recommendation
from FDA Advisory Committee
2008
- 2008.12.19
- Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP)
- 2008.12.08
- NEW PHASE II DATA SHOW SAFETY OF ONCE-DAILY ORAL FACTOR Xa INHIBITOR, DU-176b, COMPARABLE TO WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
- 2008.11.11
- ARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER
Product development agreement focused on ARQ 197, c-Met inhibitor,with discovery collaboration directed toward novel kinase inhibitors;
- 2008.10.17
- Daiichi Sankyo and Lilly Respond to Speculation
On Status of Prasugrel New Drug Application
- 2008.09.02
- Daiichi Sankyo Announces Clinical Study Data for
Oral Factor Xa Inhibitor DU-176b
- 2008.08.25
- Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
- 2008.06.24
- FDA Extends Review Period for Daiichi Sankyo, Lilly
Investigative Antiplatelet Drug, Prasugrel
- 2008.03.12
- Luitpold Pharmaceutical's INJECTAFER(TM)
(ferric carboxymaltose injection) receives non-approvable letter from FDA
- 2008.02.22
- FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with percutaneous coronary intervention
- 2008.02.20
- Daiichi Sankyo, Lilly Submit Marketing Authorization Application for
Investigational Oral Antiplatelet Drug, Prasugrel, to European
Medicines Agency
- 2008.02.04
- FDA Advisory Committee Supports Favorable Risk-Benefit Profile for Injectafer(TM)(Ferric Carboxymaltose Injection) Under Certain Indications for Use
- 2008.01.21
- Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
- 2008.01.07
- Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet
Drug, Prasugrel, with U.S. Food and Drug Administration
If Approved for Marketing in the United States, Trade Name Will be Effient(TM)
2007
- 2007.11.04
- In Landmark Phase III Head-to-Head Study, Prasugrel Statistically
Superior to Clopidogrel in Reducing Risk of Heart Attack
- 2007.11.04
- Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
- 2007.10.01
- DAIICHI SANKYO EUROPE is applying for approval of its new
combination product of Olmesartan and Amlodipin
- 2007.01.18
- Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to Clopidogrel in Patients with Acute Coronary Syndrome
2006
- 2006.10.24
- New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses
2005
- 2005.12.05
- Joint Research in Genome-based Target Discovery between Daiichi Pharmaceutical Co., Ltd. and Celestar Lexico-Sciences, Inc. has concluded
- 2005.11.17
- Large Scale Clinical Trial MEGA Study* Employing the Hyperlipidemia Drug Mevalotin®
- 2005.10.26
- Discontinuation of Clinical Studies of CS-505
(Pactimibe; Sankyo's ACAT Inhibitor)
- 2005.10.12
- Completion of the Registration of Trial Subjects for ORIENT on the Suppressive Effects of the Angiotensin II Receptor Blocker Olmetec® against the Progression of Diabetic Nephropathy
